{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:11:45Z","timestamp":1784913105790,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ek0109567h0001"],"award-info":[{"award-number":["JP21ek0109567h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03389-z","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:36:55Z","timestamp":1759991815000},"page":"6103-6117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunosuppressive Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases: Insights from Japanese Registry"],"prefix":"10.1007","volume":"42","author":[{"given":"Yudai","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshin","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yaoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Amino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusako","family":"Sera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakuoh","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kashimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadatomo","family":"Tasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyasu","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japan Pulmonary Hypertension Registry Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"3389_CR1","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.","journal-title":"Eur Respir J"},{"key":"3389_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jacasi.2022.02.011","volume":"2","author":"Y Tamura","year":"2022","unstructured":"Tamura Y, Kumamaru H, Inami T, et al. Changes in characteristics and initial treatments of pulmonary hypertension between 2008 and 2020 in Japan. JACC Asia. 2022;2:273\u201384.","journal-title":"JACC Asia"},{"key":"3389_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344.","journal-title":"N Engl J Med"},{"key":"3389_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","volume":"78","author":"KM Chin","year":"2021","unstructured":"Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021;78:1393\u2013403.","journal-title":"J Am Coll Cardiol"},{"key":"3389_CR5","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522\u201333.","journal-title":"N Engl J Med"},{"key":"3389_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"key":"3389_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","volume":"79","author":"M Kuwana","year":"2020","unstructured":"Kuwana M, Blair C, Takahashi T, et al. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020;79:626\u201334.","journal-title":"Ann Rheum Dis"},{"key":"3389_CR8","doi-asserted-by":"publisher","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","volume":"50","author":"S Gaine","year":"2017","unstructured":"Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50:1602493.","journal-title":"Eur Respir J"},{"key":"3389_CR9","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731.","journal-title":"Eur Heart J"},{"key":"3389_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/art.23303","volume":"58","author":"X Jais","year":"2008","unstructured":"Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521\u201331.","journal-title":"Arthritis Rheum"},{"key":"3389_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","volume":"82","author":"H Yasuoka","year":"2018","unstructured":"Yasuoka H, Shirai Y, Tamura Y, et al. Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2018;82:546\u201354.","journal-title":"Circ J"},{"key":"3389_CR12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1177\/0961203318756287","volume":"27","author":"Z Liu","year":"2018","unstructured":"Liu Z, Yang X, Tian Z, et al. The prognosis of pulmonary arterial hypertension associated with primary Sj\u00f6gren\u2019s syndrome: a cohort study. Lupus. 2018;27:1072\u201380.","journal-title":"Lupus"},{"key":"3389_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1253\/circj.CJ-17-0139","volume":"82","author":"Y Tamura","year":"2017","unstructured":"Tamura Y, Kumamaru H, Satoh T, et al. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension. Circ J. 2017;82:275\u201382.","journal-title":"Circ J"},{"key":"3389_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","volume":"83","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Date H, Doi S, et al. Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017). Circ J. 2019;83:842\u2013945.","journal-title":"Circ J"},{"key":"3389_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1183\/09031936.03.00038903","volume":"22","author":"P Dorfm\u00fcller","year":"2003","unstructured":"Dorfm\u00fcller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358\u201363.","journal-title":"Eur Respir J"},{"issue":"Suppl S","key":"3389_CR16","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(Suppl S):13S-24S.","journal-title":"J Am Coll Cardiol"},{"key":"3389_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.lfs.2014.01.077","volume":"118","author":"A Ogawa","year":"2014","unstructured":"Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic\/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci. 2014;118:414\u20139.","journal-title":"Life Sci"},{"key":"3389_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","volume":"30","author":"V Thakkar","year":"2016","unstructured":"Thakkar V, Lau EM. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol. 2016;30:22\u201338.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3389_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/rheumatology\/kev097","volume":"54","author":"S Kommireddy","year":"2015","unstructured":"Kommireddy S, Bhyravavajhala S, Kurimeti K, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology. 2015;54:1673\u20139.","journal-title":"Rheumatology"},{"key":"3389_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2169\/internalmedicine.56.7668","volume":"56","author":"E Sugawara","year":"2017","unstructured":"Sugawara E, Kato M, Hisada R, et al. Treatment of vasodilator-resistant mixed connective tissue disease-associated pulmonary arterial hypertension with glucocorticoid and cyclophosphamide. Intern Med. 2017;56:445\u20138.","journal-title":"Intern Med"},{"key":"3389_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","volume":"86","author":"D Launay","year":"2007","unstructured":"Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sj\u00f6gren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299\u2013315.","journal-title":"Medicine (Baltimore)"},{"key":"3389_CR22","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/annrheumdis-2021-eular.1573","volume":"80","author":"R Kishikawa","year":"2021","unstructured":"Kishikawa R, Hatano M, Ishii S, et al. Effectiveness of immunosuppressive therapy for connective tissue disease-associated pulmonary arterial hypertension. Ann Rheum Dis. 2021;80:1168\u201374.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03389-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03389-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03389-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:19Z","timestamp":1763132659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03389-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03389-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuichi Tamura received remuneration from Janssen, Bayer Yakuhin, and Daiichi Sankyo received research funds from Mochida and Nippon Shinyaku. Yu Taniguchi has received remuneration from Bayer Ltd., Janssen Pharmaceuticals Ltd., and Nippon Shinyaku Ltd., and research funds from Janssen Pharmaceuticals Ltd. Ichizo Tsujino received funding from Janssen Pharmaceutical K.K. for Joint Research, and from Nippon Shinyaku Co Ltd, Mochida Pharmaceuticals Co Ltd, Boehringer Ingelheim Japan Co Ltd, Takeyama Co Ltd, Kaneka Ltd, and Medical System Network Co Ltd as part of an endowed department. Hiromi Matsubara received research grants from Nippon Shinyaku, speaker and consultant fees from Bayer, Janssen, and MSD, speaker fees from Kaneka Medix, Mochida, Nippon Shinyaku, and Nipro. All disclosed fees and support are outside the submitted work. Shiro Adachi has received remuneration from Nippon Shinyaku Co., Ltd., Bayer Yakuhin, Ltd. and Janssen Pharmaceutical K.K.. Shiro Adachi has research funds from Nippon Shinyaku Co., Ltd., Bayer Yakuhin, Ltd., Mochida Pharmaceutical Co., Ltd.and MSD K.K.. Nobuhiro Tahara has received remuneration from Janssen Pharmaceutical K.K., Nippon Shinyaku, Mochida Pharmaceutical, Pfizer, and Bayer Yakuhin. Nobuhiro Tahara has research funds from AJanssen Pharmaceutical K.K. and Ionis Pharmaceuticals Inc. Kohtaro Abe has research funds from grant from Nippon Shinyaku, Mochida Pharmaceutical, Daiichi Sankyo, Janssen Pharmaceutical, Konica Minolta, and Daiichi Sankyo. Yoshihiro Dohi has received remuneration from Janssen Pharmaceutical K.K., Bayer Yakuhin LTd., and Nippon Shinyaku Co Ltd. Kayoko Kubota has received remuneration from Nippon shinyaku and Janssen Pharmaceutical K.K.. Hidekata Yasuoka has received remuneration from Abbvie, Asahi Kasei, Astellas Pharma, Daiichi Sankyo, Eisai. Kissei, Takeda, Tanabe Mitsubishi, Chugai, Novartis, Eli Lilly, Pfizer, Janssen, Sanofi, Teijin, Boehringer Ingelheim, Bayer, Viatris, and research funds from AbbVie, Boehringer Ingelheim, Gilead, Janssen, Nippon shinyaku, Asahi Kasei, Chugai, Eisai, Mitsubishi-Tanabe, Taisho. Satoshi Ikeda has received remuneration from Bayer Healthcare, Bristol Myers Squibb, Janssen Pharmaceutical K.K., Nippon Shinyaku, Pfizer, Viatris, and Daiichi Sankyo. Nobutaka Ikeda has received remuneration from Bayer Yakuhin, Nippon Shinyaku, Janssen Pharmaceutical K.K. Masataka Kuwana has received research grants from Boehringer Ingelheim and MBL, and lecture\/consultant fees from Asahi Kasei Pharma, AstraZeneca, Boehringer Ingelheim, Chugai, Eisai, GlaxoSmithKline, Kissei, Janssen, Mochida, and Tanabe-Mitsubishi. Yudai Tamura, Ryo Takemura, Takumi Inami, Ayako Shigeta, Masaru Hatano, Keiichi Sakurai, Koshin Horimoto, Nobuhiro Yaoita, Kazuhiro Kimura, Kayoko Kubota, Noriko Kikuchi, Yuichi Baba, Toshiro Shinke, Mari Amino, Natsumi Yamaguchi, Teruki Sato, Masaru Ishida, Fusako Sera, Naohiko Nakanishi, Hakuoh Konishi, Koichiro Kinugawa, Takeshi Kashimura, Kaoru Dohi, Kazufumi Nakamura, Soichiro Usui, Sumiaki Tanaka, Shuji Kubota, Masanori Yoshikawa, Keiichi Odagiri, Sadatomo Tasaka, Yasuchika Takeishi, Teruyasu Sugano, Koichiro Sugimura, and Koichiro Tatsumi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (approved no. R1919-13) and the International University of Health and Welfare (approval no. 5\u201321-87). The JAPHR is a prospective national registry. The institutional review boards of all the participating centers approved the study design. All the participants (including those who later died) provided written informed consent at enrolment in accordance with the Japanese Ethical Guidelines for Medical Research Involving Human Subjects. The JAPHR provided anonymized data for this study. Formal approval and permission for data access and use were obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}